The emergence of multidrug resistance is a major threat to TB care and control globally. The World Health Organization (WHO) estimates that up to half a million new cases of MDR-TB occur each year worldwide. Currently, the drug Bedaquiline is approved for use as part of a combination drug therapy for the treatment of multidrug-resistant pulmonary tuberculosis when there is no effective treatment regimen.